The Neuroleptic Malignant Syndrome: Presentation and Treatment
- 1 June 1984
- journal article
- research article
- Published by SAGE Publications in Drug Intelligence & Clinical Pharmacy
- Vol. 18 (6) , 462-465
- https://doi.org/10.1177/106002808401800601
Abstract
The neuroleptic malignant syndrome is a potentially lethal reaction following the use of antipsychotic medications. The four cardinal signs are hyperthermia, muscular rigidity, autonomic dysfunction, and altered consciousness. The differential diagnosis of the syndrome includes malignant hyperthermia of anesthesia, heat stroke, and acute lethal catatonia. Treatment consists of prompt recognition of the syndrome and initiation of intense supportive measures to manage the hyperthermia and prevent secondary complications. Clinical reports describing beneficial results from use of anticholinergic agents, amantadine, bromocriptine, and dantrolene are reviewed.Keywords
This publication has 29 references indexed in Scilit:
- NEUROLEPTIC MALIGNANT SYNDROME AND MALIGNANT HYPERTHERMIAThe Lancet, 1983
- Neurotoxicity with combined administration of lithium and a neurolepticComprehensive Psychiatry, 1982
- A Case of Neuroleptic Malignant SyndromeJournal of Clinical Psychopharmacology, 1982
- TREATMENT OF NEUROLEPTIC MALIGNANT SYNDROME WITH DANTROLENEThe Lancet, 1982
- Neuroleptic Malignant syndrome caused by dopamine‐depleting drugs in a patient with Huntington diseaseNeurology, 1981
- Neuroleptic malignant syndromeNeurology, 1981
- Neuroleptic Malignant SyndromeArchives of Neurology, 1980
- Malignant neuroleptic syndrome: An atypical casePsychosomatics, 1979
- Fever, Tachycardia, and Hypertension With Acute Catatonic SchizophreniaArchives of internal medicine (1960), 1978
- Malignant hyperthermia of anesthesiaThe American Journal of Surgery, 1973